Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), Boston Scientific (BSX – Research Report) and Harrow Health (HROW – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
X4 Pharmaceuticals (XFOR)
Guggenheim analyst Michael Schmidt maintained a Buy rating on X4 Pharmaceuticals yesterday and set a price target of $12.00. The company’s shares closed last Tuesday at $4.23.
According to TipRanks.com, Schmidt is a 5-star analyst with an average return of
Currently, the analyst consensus on X4 Pharmaceuticals is a Moderate Buy with an average price target of $12.00.
See Insiders’ Hot Stocks on TipRanks >>
Boston Scientific (BSX)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Boston Scientific. The company’s shares closed last Tuesday at $71.20, close to its 52-week low of $66.80.
According to TipRanks.com, Newitter is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $106.63, which is a 52.1% upside from current levels. In a report issued on March 4, TD Cowen also maintained a Buy rating on the stock with a $100.00 price target.
Harrow Health (HROW)
In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Harrow Health, with a price target of $91.00. The company’s shares closed last Tuesday at $35.23.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of
Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $70.00, representing a 98.9% upside. In a report issued on March 3, TipRanks – Google also upgraded the stock to Buy with a $59.00 price target.
